CALA Calithera Biosciences Inc.

4.09
0  0%
Previous Close 4.09
Open
Price To Book 1.51
Market Cap 160,495,408
Shares 39,240,931
Volume 733
Short Ratio
Av. Daily Volume 268,973

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but will not pursue development.
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 top-line data June 17, 2019 noted PFS 3.8 months compared to 1.9 months for everolimus alone.
CB-839 + AFINITOR (everolimus)‎ - ENTRATA
Clear cell renal cell carcinoma
Phase 1 oral presentation at ASCO, June 5, 2017.
CX-1158-101
Solid tumors - cancer
Phase 1/2 enrollment commenced August 2016. Oral presentation November 11, 2017 at 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer
Phase 2 poster at ASCO GU February 16, 2019 noted 5/13 ORR.
CB-839 + Cabozantinib (CANTATA)
Renal cell carcinoma
Phase 2 portion of trial is ongoing.
CB-839 + Panitumumab
Colorectal cancer
Phase 1 poster at ASCO June 4, 2018 8am.
CB-839 + Capecitabine
Solid tumors
Phase 1 presentation at ASCO June 2018. PFS 26 weeks.
CB-839 plus capecitabine
Solid tumors
Phase 1/2 trial initiation announced March 26, 2019.
CB-839 plus talazoparib
Triple negative breast cancer
Phase 1/2 data due 2H 2019.
INCB001158
Solid tumors
Phase 1/2 trial to be initiated 2Q 2019.
Ibrance and talazoparib + CB-839
KRAS mutated NSCLC
Phase 1 trial initiation announced February 21, 2019 with trial completion 2019.
CB-280
Cystic fibrosis

Latest News

  1. Did You Miss Calithera Biosciences's (NASDAQ:CALA) 37% Share Price Gain?
  2. Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
  3. Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more
  4. Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy
  5. Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma
  6. Edited Transcript of CALA earnings conference call or presentation 9-May-19 9:00pm GMT
  7. Calithera Biosciences, Inc. (CALA) Q1 2019 Earnings Call Transcript
  8. Calithera: 1Q Earnings Snapshot
  9. Calithera Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights 
  10. Analysts Estimate Calithera (CALA) to Report a Decline in Earnings: What to Look Out for
  11. How Many Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Do Institutions Own?
  12. Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019
  13. Calithera (CALA) Initiates Phase I/II Study of Telaglenastat
  14. Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
  15. Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT
  16. Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights
  17. Calithera to Present at Cowen & Company 39th Annual Healthcare Conference
  18. Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
  19. Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019
  20. Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference